Skip to main content

Checkmate Pharmaceuticals, Inc.

CMPIDelisted May 31, 2022
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001651431

Checkmate Pharmaceuticals, Inc. was delisted on May 31, 2022; its insiders filed their last Form 4 on May 31, 2022; 26 institutions reported holding it in 13F filings for Q1 2022, worth $54.8M in total; no superinvestor held it.

Q3 2021 vs. Q2 2021

How the institutions holding Checkmate Pharmaceuticals, Inc. changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of CMPI: Q2 2021 compared with Q3 2021
MeasureQ2 2021Q3 2021Change
Holders3432−2
Shares16.3M16.4M+30.5K (+0.2%)
Value$97.3M$64.5M−$32.8M (−33.7%)

New holders (4)

Institutions that held Checkmate Pharmaceuticals, Inc. at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to CMPI in Q3 2021
InstitutionSharesValue% of portfolio
Jacobs Levy Equity Management, Inc36,511$145.0K0.00%
State Street Corp11,087$44.0K0.00%
Tower Research Capital LLC (TRC)1,426$6.00K0.00%
Hall Laurie J Trustee100,530$00.00%

Sold out (6)

Institutions that held Checkmate Pharmaceuticals, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.

Institutions that sold out of CMPI in Q3 2021
InstitutionShares, Q2 2021Value, Q2 2021
Deutsche Bank AG134,760$803.0K
Millennium Management LLC40,422$241.0K
Alberta Investment Management Corp25,000$149.0K
Advisory Services Network, LLC7,800$46.0K
New York State Common Retirement Fund77$0
Citigroup Inc1$0